Operating
Benefit from Receivables
Medtronic Benefit from Receivables increased by 3.7% to $28.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric grew by 55.6%, from $18.00M to $28.00M. Over 4 years (FY 2021 to FY 2025), Benefit from Receivables shows relatively stable performance with a -1.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2014
Last reportedQ1 2026Aug 26, 2025
Metric ID:
csco_benefit_from_receivablesHistorical Data
18 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.00M | $15.00M | $26.00M | $8.00M | $9.00M | $15.00M | $22.00M | $17.00M | $19.00M | $21.00M | $24.00M | $17.00M | $28.00M | $18.00M | $48.00M | $30.00M | $27.00M | $28.00M |
| QoQ Change | — | -40.0% | +73.3% | -69.2% | +12.5% | +66.7% | +46.7% | -22.7% | +11.8% | +10.5% | +14.3% | -29.2% | +64.7% | -35.7% | +166.7% | -37.5% | -10.0% | +3.7% |
| YoY Change | — | — | — | — | -64.0% | +0.0% | -15.4% | +112.5% | +111.1% | +40.0% | +9.1% | +0.0% | +47.4% | -14.3% | +100.0% | +76.5% | -3.6% | +55.6% |
Range$8.00M – $48.00M
CAGR+2.7%
Avg YoY Growth+32.5%
Median YoY Growth+24.5%
Benefit from Receivables at Other Companies
Frequently Asked Questions
- What is Medtronic's benefit from receivables?
- Medtronic (MDT) reported benefit from receivables of $28.00M in Q2 2025.
- How has Medtronic's benefit from receivables changed year-over-year?
- Medtronic's benefit from receivables increased by 55.6% year-over-year, from $18.00M to $28.00M.
- What is the long-term trend for Medtronic's benefit from receivables?
- Over 4 years (2021 to 2025), Medtronic's benefit from receivables has grown at a -1.6% compound annual growth rate (CAGR), from $131.00M to $123.00M.